News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Elixir Pharmaceuticals Sees IPO of 5 Million Shares at $14-$16 each
December 18, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dec 18 (Reuters) - Elixir Pharmaceuticals Inc, a company focused on drugs for metabolic diseases like diabetes and obesity, registered its initial public offering of 5 million shares at an estimated price of $14 to $16 per share.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
IPO
UPDATE: Neuroscience Biotech LB Pulls Off Upsized $285M IPO
September 11, 2025
·
2 min read
·
Annalee Armstrong
Mergers & Acquisitions
Hectic Markets, Emotions Lead Biotechs To Tack On CVRs
September 10, 2025
·
6 min read
·
Annalee Armstrong
Mergers & Acquisitions
Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises
September 9, 2025
·
2 min read
·
Annalee Armstrong
IPO
SPACs Line Up To Clear Biotech’s IPO Backlog
September 3, 2025
·
6 min read
·
Annalee Armstrong
